恩度联合化疗治疗老年晚期非小细胞肺癌25例临床护理.docVIP

恩度联合化疗治疗老年晚期非小细胞肺癌25例临床护理摘 要 目的:探讨恩度（重组人血管内皮抑制素）联合含铂化疗方案治疗老年晚期非小细胞肺癌（NSCLC）的疗效和不良反应护理。方法:将老年晚期NSCLC患者50例随机分为两组各25例，对照组采用NP方案（长春瑞滨+顺铂）治疗，观察组采用NP方案+恩度治疗，21 d为1个周期，2个周期治疗结束后对其疗效、生活质量及不良反应进行评价,并随访至少1年统计生存率。结果:观察组有效率为80.0%，6个月、12个月生存率分别为96.0%、88.0%，生活质量提高率为76.0%；对照组有效率为 44.0%，6个月、12个月生存率分别为44.0%、20.0%，生活质量提高率为20.0%。以上两组比较差异有统计学意义（P＜0.05）。结论:恩度联合化疗治疗老年晚期NSCLC，可提高患者疗效，延长生存期，提高生活质量，不良反应少。 关键词 恩度;化疗;老年晚期非小细胞肺癌;护理 中图分类号：R473.73 文献标识码：A 文章编号：1006-7256（2011)15-0001-03 Clinical nursing care in the treatment of 25 patients with advanced non-small cell lung cancer by Endostar combination chemotherapy Li Qing, Liu Nai-ying, Li Shan-shan, et al (Affiliated Shandong Provincial Hospital to Shandong University, Jinan Shandong 250021, China) Abstract Objective: To observe the efficacy of Endostar (Receombinant Human Endostatin) combined with platinum based chemotherapy in the treatment of the elderly patients with advanced non-small cell lung cancer (NSCLC) and nursing care of adverse reactions. Methods: 50 elderly patients with advanced NSCLC were randomly divided into control group and observation group (25 patients for each group). The chemotherapy with NP program (Vinorelbine plus Cisplatin) was used in the control group and NP program + Endostar was applied in the observation group. One treatment period lasted for 21 days. The efficacy of the treatment, quality of life of the patients and the adverse reactions were evaluated after two treatment periods. The survival rate was followed up for at least one year and processed statistically. Results: The effective rate was 80.0% and the survival rates of 6 and 12 months were respectively 96.0% and 88.0% and the improved rate of quality of life was 76.0% in the observation group; the effective rate was 44.0% and the survival rates of 6 and 12 months were respectively 44.0% and 20.0% and the improved rate of quality of life was 20.0% in the control group and the differences between these two groups were significant (P